find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
19
Clinical Trials
Breast Cancer Clinical Trials
Phase III
Enrolling
nct/study# NCT06982521 / RLY-2608-102
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor
Learn More
Breast Cancer Clinical Trials
N/A
Enrolling
nct/study# N/A / RW-SURVIVAL-HER2
Real-World Survival Among Patients with HER2-Positive and HER2-Low Metastatic Malignancies Who Received HER2-Targeting Agents
Learn More
Breast Cancer Clinical Trials
N/A
Enrolling
nct/study# NCT03111108 / 2016-0215
Endocrine disruptors, obesity, and breast density among perimenopausal women
Learn More
Breast Cancer Clinical Trials
Phase III
Enrolling
nct/study# NCT06492616 / STML-ELA-0422
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence – A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
Learn More
Breast Cancer Clinical Trials
Unspecified
Enrolling
nct/study# NCT05812807 / A012103
OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY
Learn More
Breast Cancer Clinical Trials
Phase III
Enrolling
nct/study# NCT05894239 / WO44263
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination with Phesgo Versus Placebo in Combination with Phesgo as Maintenance Therapy After First Line Induction Therapy in Participants with PIK3CA Mutated HER2 Positive Locally Advanced or Metastatic Breast Cancer
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.